This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
by Sundeep Ganoria
AbbVie's neuroscience franchise posts strong first-half growth, with Vyalev accelerating and tavapadon poised to add another potential growth driver.
ABBVPositive Net Change BIIBPositive Net Change JNJPositive Net Change
biotechs earnings marijuana pharmaceuticals
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?
by Sundeep Ganoria
ANI Pharmaceuticals' low valuation and strong 2026 growth outlook face a key test as Cortrophin execution risk rises.
ANIPPositive Net Change REGNPositive Net Change ABBVPositive Net Change
biotechs medical
ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growth
by Sundeep Ganoria
Cortrophin guidance cuts put more pressure on ANI Pharmaceuticals' second-half execution as the drug must deliver a sharper growth ramp.
ANIPPositive Net Change REGNPositive Net Change ABBVPositive Net Change
biotechs medical pharmaceuticals
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains
by Zacks Equity Research
CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.
CRMDPositive Net Change RGENNegative Net Change ACIUPositive Net Change AMRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Can Asceniv Help ADMA Stock Combat IG Market Challenges?
by Ekta Bagri
Asceniv drives ADMA's growth with rising adoption and real-world evidence, while competitive pressure weighs on Bivigam sales.
ADMAPositive Net Change GRFSNegative Net Change TAKPositive Net Change
biotechs earnings medical pharmaceuticals
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
by Zacks Equity Research
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
ALLONegative Net Change RGENNegative Net Change ANIKPositive Net Change
biotechs earnings medical
LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth
by Zacks Equity Research
Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.
LQDANegative Net Change UTHRPositive Net Change RGENNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
by Ahan Chakraborty
NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.
NVOPositive Net Change LLYPositive Net Change VKTXNegative Net Change GPCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Undervalued Price-to-Book Stocks Worth Buying in August
by Kinjel Shah
BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.
BMRNPositive Net Change IVZNegative Net Change ROCKNegative Net Change CNCPositive Net Change HPENegative Net Change
biotechs construction finance medical pharmaceuticals
Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?
by Ekta Bagri
Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.
BMYPositive Net Change PFEPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals